Showing results (211-220 of 369) with videos related to
Sort By:
Pageof 37
JAMA Oncology|June 30, 2018
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate CancerHoward I Scher, Ryon P Graf, Nicole A Schreiber, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2017
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical TrialsGlenn Heller, Robert McCormack, Thian Kheoh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapyDavid B Agus, Christopher J Sweeney, Michael J Morris, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Pharmacokinetics and toxicity of weekly docetaxel in older patientsArti Hurria, Mark T Fleming, Sharyn D Baker, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerDavid B Solit, S Percy Ivy, Catherine Kopil, et al.Cancer Cell|December 30, 2014
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3KβSarit Schwartz, John Wongvipat, Cath B Trigwell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2012
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumorsMargaret M Centenera, Joanna L Gillis, Adrienne R Hanson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancerHoward I Scher, Glenn Heller, Arturo Molina, et al.JAMA Oncology|March 10, 2018
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical TrialDana E Rathkopf, Tomasz M Beer, Yohann Loriot, et al.European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPERAnthony M Joshua, Andrew Armstrong, Megan Crumbaker, et al.Pageof 37